Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/57750| Conference/Presentation Title: | Unlocking Asthma Remission: Key Insights from an Expert Roundtable Discussion. | Authors: | Thomas D.;Lewthwaite H.;Gibson P.;Majellano E.;Clark V.;Fricker M.;Hamada Y.;Anderson G.;Backer V.;Bardin P. ;Beasley R.;Chien J.;Farah C.;Harrington J.;Harvey E.;Hew M.;Holland A.;Jenkins C.;Katelaris C.;Katsoulotos G.;Murray K.;Peters M.;Thomas R.;Tonga K.;Upham J.;Wark P.;Mcdonald V. | Monash Health Department(s): | Monash University - School of Clinical Sciences at Monash Health Monash University - School of Public Health and Preventative Medicine |
Institution: | (Thomas, Lewthwaite, Gibson, Majellano, Clark, Fricker, Murray, Thomas) Centre of Excellence in Treatable Traits, Hunter Medical Research Institute Asthma and Breathing Programme; College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, Australia (Hamada, Harvey, Mcdonald) Clinical Research Centre for Allergy and Rheumatology, National Hospital Organisation Sagamihara National Hospital, Sagamihara, Japan (Anderson) Lung Health Research Centre, Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, Australia (Backer) Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University hospital, Copenhagen, Denmark (Bardin) Lung and Sleep Medicine, Monash University, Medical Centre and Hudson Institute, Melbourne, Australia (Beasley) Medical Research Institute of New Zealand, Wellington, New Zealand (Chien) Department of Sleep and Respiratory Medicine, Westmead Hospital; Faculty of Medicine and Health, University of Sydney, Sydney, Australia (Farah, Tonga) Faculty of Medicine and Health, University of Sydney; Department of Thoracic Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia (Harrington) Centre of Excellence in Treatable Traits, Hunter Medical Research Institute Asthma and Breathing Programme; Hunter New England Local Health District, John Hunter Hospital, Newcastle, Australia (Hew) Allergy, Asthma and Clinical Immunology, Alfred Health, School of Public health and Preventive Medicine, Monash University, Melbourne, Australia (Holland) School of Translational Medicine, Monash University, Melbourne, Australia (Jenkins) Faculty of Medicine and Health, University of Sydney; Department of Thoracic Medicine, Concord Hospital, Sydney, Australia (Katelaris) School of Medicine, Western Sydney University; Immunology and Allergy Unit, Campbelltown Hospital, Sydney, Australia (Katsoulotos) St George Specialist Centre; St Vincent's Clinic, School of Medicine, University of Notre Dame, Sydney, Australia (Peters) Department of Thoracic Medicine, Concord Hospital; Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia (Upham) Department of Respiratory Medicine, Princess Alexandra Hospital; Faculty of Medicine, University of Queensland, Brisbane, Australia (Wark) Centre of Excellence in Treatable Traits, Hunter Medical Research Institute Asthma and Breathing Programme; College of Health, Medicine and Wellbeing, University of Newcastle; School of Translational Medicine, Melbourne, Australia |
Presentation/Conference Date: | 31-Mar-2026 | Copyright year: | 2025 | Publisher: | European Respiratory Society | Publication information: | European Respiratory Journal. Conference: European Respiratory Society Congress, ERS 2025. Amsterdam Netherlands. 66(Supplement 69) (no pagination), 2025. Date of Publication: 01 Sep 2025. | Abstract: | Background: Treatment targets in severe asthma have evolved towards a remission-focused paradigm guided by precision medicine. However, the concept is still emerging. Objective(s): To understand the strengths, weaknesses, confounders, application and future of the current construct of asthma remission. Method(s): A hybrid face-to-face and virtual roundtable discussion was held on the 30th of April 2024. The summary of discussions is narratively synthesised. Result(s): The participants (n=27 international asthma experts) observed that between one in three to one in five people treated with biologics/macrolides experience low disease activity over a sustained period. Labelling the attained clinical state as clinical remission is useful as a clinical, policy and scientific tool. Current remission rates vary significantly due to definition variability. The minimum requirements of asthma remission have been proposed. When assessing remission, it is essential to consider confounding factors. More research is required to reach an acceptable definition, and including the patient's voice in such research is essential. The themes discussed and the suggestions are summarised in Figure 1. Conclusion(s): The concept of treatment-induced clinical remission is possible and valuable in asthma. However, further refinement of the definition is required. | Conference Name: | European Respiratory Society Congress, ERS 2025 | Conference Start Date: | 2025-09-27 | Conference End Date: | 2025-10-01 | Conference Location: | Amsterdam, Netherlands | DOI: | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1183/13993003.congress-2025.PA3651 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/57750 | Type: | Conference Abstract | Subjects: | asthma health status personalized medicine remission biological product macrolide |
| Appears in Collections: | Conference Abstracts |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.